- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 13.11. | Longeveron reports Q3 results | 1 | Seeking Alpha | ||
| 12.11. | Longeveron Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 11.11. | A Look Ahead: Longeveron's Earnings Forecast | 4 | Benzinga.com | ||
| LONGEVERON Aktie jetzt für 0€ handeln | |||||
| 11.11. | Longeveron ernennt Devin Blass zum neuen CTO | 2 | Investing.com Deutsch | ||
| 11.11. | Longeveron names Devin Blass as new CTO | 1 | Investing.com | ||
| 11.11. | Longeveron Appoints Devin Blass as Chief Technology Officer and SVP of Chemistry, Manufacturing and Controls (CMC) | 2 | GlobeNewswire (USA) | ||
| 04.11. | Peeling Back The Layers: Exploring Longeveron Through Analyst Insights | 1 | Benzinga.com | ||
| 27.10. | Longeveron Presents Lomecel-B Long-term Transplant-free Survival Data in Hypoplastic Left Heart Syndrome (HLHS) at the Congenital Heart Surgeons' Society (CHSS) 51st Annual Meeting | 61 | GlobeNewswire (Europe) | Oral presentation highlights findings that patients treated with Lomecel-BTM in ELPIS I, in an open-label follow-on study, experienced 5-year survival after stage 2 Glenn surgery of 100% with none... ► Artikel lesen | |
| 09.10. | Longeveron® Lomecel-B 5-Year Long-term Transplant-free Survival Data in HLHS Selected for Oral Presentation at the Congenital Heart Surgeons' Society (CHSS) 51st Annual Meeting | 1 | GlobeNewswire (USA) | ||
| 07.10. | Longeveron® to Present at the UBS Virtual Organ Restoration and Cell Therapy Day | 3 | GlobeNewswire (USA) | ||
| 02.10. | Longeveron® to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference | 1 | GlobeNewswire (USA) | ||
| 26.09. | BioMedNewsBreaks - Longeveron Inc. (NASDAQ: LGVN) to Participate at the Cell & Gene Meeting on the Mesa | 1 | iNVEZZ.com | ||
| 26.09. | Longeveron to Attend Alliance for Regenerative Medicine's Cell & Gene Meeting on the Mesa | 2 | GlobeNewswire (USA) | ||
| 26.08. | Longeveron to Present at the H.C. Wainwright 26th Annual Global Investment Conference | 1 | GlobeNewswire (USA) | ||
| 15.08. | Longeveron reports Q2 results | 4 | Seeking Alpha | ||
| 15.08. | Earnings call: Longeveron reports progress on Lomecel-B, eyes FDA talks | 2 | Investing.com | ||
| 06.08. | Longeveron Inc. - S-1, General form for registration of securities | 1 | SEC Filings | ||
| 29.07. | Longeveron surges 14% on phase 2 Lomecel-B Alzheimer's data | 3 | Seeking Alpha | ||
| 29.07. | Longeveron (LGVN) Stock Pops on Phase 2 Trial Updates | 2 | InvestorPlace | ||
| 29.07. | Why Is Alzheimer's-Focused Longeveron Stock Trading Higher On Monday? | 3 | Benzinga.com |
Seite:
1 2 3 4 Weiter >>
63 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EPIGENOMICS | 0,900 | -21,74 % | EQS-AFR: Epigenomics AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß § 114, 115, 117 WpHG | EQS Vorabbekanntmachung Finanzberichte: Epigenomics AG
/ Vorabbekanntmachung über die Veröffentlichung von Rechnungslegungsberichten
Epigenomics AG: Vorabbekanntmachung über die... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,384 | +3,78 % | Defence Therapeutics Inc.: Defence Therapeutics Announces Securities for Debenture Financing | Vancouver, British Columbia--(Newsfile Corp. - November 14, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company... ► Artikel lesen | |
| CYTODYN | 0,126 | 0,00 % | CytoDyn Inc.: CytoDyn Announces FDA Clearance of Its Phase II Oncology Trial | VANCOUVER, Washington, Nov. 04, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential... ► Artikel lesen | |
| GINKGO BIOWORKS | 6,000 | -0,83 % | Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Sees Significant Drop in Short Interest | ||
| RECURSION PHARMACEUTICALS | 5,735 | -5,05 % | Recursion Pharmaceuticals, Inc.: Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery | Recursion unveils post-combination technology-enabled portfolio with more than 10 clinical and preclinical programs, 10 advanced discovery programs, and more than 10 partnered programsPlatform will... ► Artikel lesen | |
| BEAM THERAPEUTICS | 23,720 | -3,10 % | Beam Therapeutics Inc. (NASDAQ:BEAM) Sees Large Increase in Short Interest | ||
| ONCOLYTICS BIOTECH | 0,945 | 0,00 % | Oncolytics Biotech Inc. (NASDAQ:ONCY) Q3 2024 Earnings Call Transcript | ||
| ANAVEX LIFE SCIENCES | 8,634 | +7,36 % | Anavex Reports Promising EEG Biomarker Results From Phase 2 Study Of ANAVEX 3-71 For Schizophrenia | WASHINGTON (dpa-AFX) - Anavex Life Sciences Corp. (AVXL) announced promising preliminary electroencephalography or EEG biomarker results from Part A of its ongoing placebo-controlled Phase 2... ► Artikel lesen | |
| CERUS | 1,578 | 0,00 % | Cerus Corporation Announces Third Quarter 2024 Financial Results | CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced financial results for its third quarter and nine months ended September 30, 2024.
Total revenue for the three... ► Artikel lesen | |
| ARCTURUS THERAPEUTICS | 16,400 | +1,30 % | Arcturus Therapeutics Holdings Inc.: Arcturus Therapeutics to Present at Jefferies London Healthcare Conference | Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities... ► Artikel lesen | |
| ASSERTIO | 0,960 | +1,05 % | Assertio Holdings-Direktorin Heather Mason kauft Aktien im Wert von 60.000 US-Dollar | ||
| SIGA TECHNOLOGIES | 6,280 | +0,48 % | SIGA Technologies - TPOXX chalks up another DoD contract win | SIGA Technologies announced another contract win with the US Department of Defense (DoD), which is for the procurement of c $9m in TPOXX. This is the third DoD contract win in roughly three years for... ► Artikel lesen | |
| ADMA BIOLOGICS | 21,250 | -0,56 % | Adma Biologics Aktie: Erholung nach starkem Kursrückgang | ||
| VIR BIOTECHNOLOGY | 6,700 | -0,59 % | Needham & Company LLC Reaffirms Buy Rating for Vir Biotechnology (NASDAQ:VIR) | ||
| WINDTREE THERAPEUTICS | 0,510 | 0,00 % | WINDTREE THERAPEUTICS INC /DE/ - NT 10-Q, Notification of inability to timely file Form 10-Q or 10-QSB |
LONGEVERON INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 1,845 Euro und damit -1,34 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu LONGEVERON INC finden Sie auf Wallstreet Online.
